BiosimilarDrug
HLX04 clinical trials
Also written HLX04.
A product of Bevacizumab; its studies count on that page too.
- studies test it
- 8
- open now
- 1
- in phase 3
- 3
- first study started
- 2017
Keep track of what changes. Save the HLX04 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Studies by the year they started
8 studies that test it; most in 2018 (2)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 2 |
| 2021 | 1 |
| 2022 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 3
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 6 · Other 2
Shanghai Henlius Biotech (6) · Sir Run Run Shaw Hospital (1) · Shanghai Zhongshan Hospital (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses HLX04 is read from its arms, and is right about nine times in ten.
Testing it · 8
- First-Line Treatment Induced With mFOLFOX6 and HLX04 Regimen, Following Combined With Serplulimab in MSS Initially Unresectable Metastatic Colorectal CancerNot yet recruitingPhase 2Sir Run Run Shaw HospitalNCT06491355Written as mfolfox6 and hlx04 regimen and Serplulimab
- A Clinical Study to Compare the Efficacy, Safety and Immunogenicity of HLX04 and Bevacizumab Combined XELOX or mFOLFOX6 in the First-line Treatment of mCRCCompletedPhase 3Shanghai Henlius BiotechNCT03511963Written as HLX04 100 mg in 4 ml Injection
- A Study of HLX10 in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04 Compared With Carboplatin+Pemetrexed in 1L Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingPhase 3Shanghai Henlius BiotechNCT03952403Written as HLX04, a bevacizumab biosimilar
- Pharmacokinetic, Safety and Immunogenicity Phase I Study of HLX04 Versus Avastin® in Healthy Male SubjectsCompletedPhase 1Shanghai Henlius BiotechNCT03483649Written as HLX04
- A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCCWithdrawnPhase 3Shanghai Henlius BiotechNCT04465734Written as HLX04
- A Clinical Study Evaluating the Use of HLX10 in Combination With HLX04 for the Treatment of Advanced Hepatocellular Carcinoma (HCC) PatientsStatus unknownPhase 2Shanghai Henlius BiotechNCT03973112Written as HLX04 5mg/kg
- Combination Therapy of HAIC and HLX10 and HLX04 in HCC With Major Portal Vein Tumor ThrombosisStatus unknownPhase 2Shanghai Zhongshan HospitalNCT04947826Written as HLX04 (VEGF antibody)
- A Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Anti-PD-1 Antibody (HLX10) in Combination With Avastin Biosimilar (HLX04) in Patients With Advanced Solid TumorsStatus unknownPhase 1Shanghai Henlius BiotechNCT03757936Written as HLX04
Given in every arm · 4 — HLX04 is usual care beside what is tested
- A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.RecruitingPhase 2Shanghai Henlius BiotechNCT06349980Written as HLX04
- A Clinical Study to Evaluate Efficacy and Safety of Serplulimab（HLX10） Combined With Bevacizumab（HLX04) and Chemotherapy (XELOX) in Patients With Metastatic Colorectal Cancer (mCRC)RecruitingPhase 2/3Shanghai Henlius BiotechNCT04547166Written as HLX04、
- Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment FailureRecruitingPhase 2Henan Cancer HospitalNCT06334757Written as Bevacizumab Biosimilar HLX04
- HLX07 Combination Therapy or Motherapy in Patient With Advanced Hepatocellular CarcinomaStatus unknownPhase 2Shanghai Henlius BiotechNCT05290220Written as HLX04